This comprehensive report provides an in-depth analysis of the global multi-cancer screening market, forecasting its trajectory from 2025 through 2032. The study examines key segments, including laboratory-developed tests and in-vitro diagnostics, across diverse applications such as hospitals and clinics. By evaluating major players like Guardant Health and GRAIL, the report highlights competitive strategies, regional growth trends in the Americas, APAC, and Europe, and emerging opportunities within this rapidly evolving diagnostic landscape.

Multi Cancer Screening Industry Forecast Report

Executive Overview

Global Market Outlook

The global Multi Cancer Screening market is projected to experience significant growth from 2025 through 2032, expanding at a consistent compound annual growth rate during the forecast period from 2026 to 2032.

Regional Market Projections

• United States: The market for Multi Cancer Screening in the United States is estimated to increase from 2025 through 2032, growing at a steady compound annual growth rate.
• China: The Chinese market for Multi Cancer Screening is estimated to undergo expansion from 2025 to 2032, characterized by a sustained compound annual growth rate.
• Europe: The European market for Multi Cancer Screening is expected to grow from 2025 through 2032, maintaining a positive compound annual growth rate.

Report Scope and Methodology

This newest research report from LPI (LP Information), titled “Multi Cancer Screening Industry Forecast,” evaluates past sales and reviews total global Multi Cancer Screening sales in 2025. It provides a comprehensive analysis by region and market sector of projected Multi Cancer Screening sales for the period of 2026 through 2032.

With Multi Cancer Screening sales broken down by region, market sector, and sub-sector, this report delivers a detailed analysis of the global Multi Cancer Screening industry in US$ millions.

Analytical Focus

This Insight Report provides a comprehensive analysis of the global Multi Cancer Screening landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyzes the strategies of leading global companies, focusing on:

• Multi Cancer Screening portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

This analysis is designed to provide a deeper understanding of these firms’ unique positions within an accelerating global Multi Cancer Screening market.

Market Drivers and Forecast Nuance

The report evaluates key market trends, drivers, and affecting factors shaping the global outlook for Multi Cancer Screening. It breaks down the forecast by type, application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global Multi Cancer Screening industry.

Market Segmentation

By Type

• Laboratory Developed Tests (LDTs)
• In-Vitro Diagnostics (IVDs)

By Application

• Hospitals
• Clinic

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Market Dynamics

Global key Multi Cancer Screening players include Guardant Health, GRAIL, Burning Rock, Thermo Fisher Scientific, and Exact Sciences Corporation, among others. In terms of revenue, the global two largest companies occupied a significant market share in 2025.

Key Vendors

The following companies have been profiled based on inputs gathered from primary experts and an analysis of the companies' coverage, product portfolios, and market penetration:

• Guardant Health
• GRAIL
• Burning Rock
• Thermo Fisher Scientific
• Exact Sciences Corporation
• Fulgent Genetics
• Genecast Biotechnology
• Agilent Technologies
• Atara Biotherapeutics
• Konica Minolta
• Tempus
• Myriad Genetics
• Laboratory Corporation

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Multi Cancer Screening Market Size (2021-2032)

    • 2.1.2 Multi Cancer Screening Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Multi Cancer Screening by Country/Region (2021, 2025 & 2032)

  • 2.2 Multi Cancer Screening Segment by Type

    • 2.2.1 Laboratory Developed Tests (LDTs)

    • 2.2.2 In-Vitro Diagnostics (IVDs)

    • 2.2.3 Multi Cancer Screening Market Size by Type

      • 2.2.3.1 Multi Cancer Screening Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.3.2 Global Multi Cancer Screening Market Size Market Share by Type (2021-2026)

  • 2.3 Multi Cancer Screening Segment by Application

    • 2.3.1 Hospitals

    • 2.3.2 Clinic

    • 2.3.3 Multi Cancer Screening Market Size by Application

      • 2.3.3.1 Multi Cancer Screening Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.3.2 Global Multi Cancer Screening Market Size Market Share by Application (2021-2026)

• 3 Multi Cancer Screening Market Size by Player

  • 3.1 Multi Cancer Screening Market Size Market Share by Player

    • 3.1.1 Global Multi Cancer Screening Revenue by Player (2021-2026)

    • 3.1.2 Global Multi Cancer Screening Revenue Market Share by Player (2021-2026)

  • 3.2 Global Multi Cancer Screening Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Multi Cancer Screening by Region

  • 4.1 Multi Cancer Screening Market Size by Region (2021-2026)

  • 4.2 Global Multi Cancer Screening Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Multi Cancer Screening Market Size Growth (2021-2026)

  • 4.4 APAC Multi Cancer Screening Market Size Growth (2021-2026)

  • 4.5 Europe Multi Cancer Screening Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Multi Cancer Screening Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Multi Cancer Screening Market Size by Country (2021-2026)

  • 5.2 Americas Multi Cancer Screening Market Size by Type (2021-2026)

  • 5.3 Americas Multi Cancer Screening Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Multi Cancer Screening Market Size by Region (2021-2026)

  • 6.2 APAC Multi Cancer Screening Market Size by Type (2021-2026)

  • 6.3 APAC Multi Cancer Screening Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Multi Cancer Screening Market Size by Country (2021-2026)

  • 7.2 Europe Multi Cancer Screening Market Size by Type (2021-2026)

  • 7.3 Europe Multi Cancer Screening Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Multi Cancer Screening by Region (2021-2026)

  • 8.2 Middle East & Africa Multi Cancer Screening Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Multi Cancer Screening Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Multi Cancer Screening Market Forecast

  • 10.1 Global Multi Cancer Screening Forecast by Region (2027-2032)

    • 10.1.1 Global Multi Cancer Screening Forecast by Region (2027-2032)

    • 10.1.2 Americas Multi Cancer Screening Forecast

    • 10.1.3 APAC Multi Cancer Screening Forecast

    • 10.1.4 Europe Multi Cancer Screening Forecast

    • 10.1.5 Middle East & Africa Multi Cancer Screening Forecast

  • 10.2 Americas Multi Cancer Screening Forecast by Country (2027-2032)

    • 10.2.1 United States Market Multi Cancer Screening Forecast

    • 10.2.2 Canada Market Multi Cancer Screening Forecast

    • 10.2.3 Mexico Market Multi Cancer Screening Forecast

    • 10.2.4 Brazil Market Multi Cancer Screening Forecast

  • 10.3 APAC Multi Cancer Screening Forecast by Region (2027-2032)

    • 10.3.1 China Multi Cancer Screening Market Forecast

    • 10.3.2 Japan Market Multi Cancer Screening Forecast

    • 10.3.3 Korea Market Multi Cancer Screening Forecast

    • 10.3.4 Southeast Asia Market Multi Cancer Screening Forecast

    • 10.3.5 India Market Multi Cancer Screening Forecast

    • 10.3.6 Australia Market Multi Cancer Screening Forecast

  • 10.4 Europe Multi Cancer Screening Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Multi Cancer Screening Forecast

    • 10.4.2 France Market Multi Cancer Screening Forecast

    • 10.4.3 UK Market Multi Cancer Screening Forecast

    • 10.4.4 Italy Market Multi Cancer Screening Forecast

    • 10.4.5 Russia Market Multi Cancer Screening Forecast

  • 10.5 Middle East & Africa Multi Cancer Screening Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Multi Cancer Screening Forecast

    • 10.5.2 South Africa Market Multi Cancer Screening Forecast

    • 10.5.3 Israel Market Multi Cancer Screening Forecast

    • 10.5.4 Turkey Market Multi Cancer Screening Forecast

  • 10.6 Global Multi Cancer Screening Forecast by Type (2027-2032)

  • 10.7 Global Multi Cancer Screening Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Multi Cancer Screening Forecast

• 11 Key Players Analysis

  • 11.1 Guardant Health

    • 11.1.1 Guardant Health Company Information

    • 11.1.2 Guardant Health Multi Cancer Screening Product Offered

    • 11.1.3 Guardant Health Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Guardant Health Main Business Overview

    • 11.1.5 Guardant Health Latest Developments

  • 11.2 GRAIL

    • 11.2.1 GRAIL Company Information

    • 11.2.2 GRAIL Multi Cancer Screening Product Offered

    • 11.2.3 GRAIL Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 GRAIL Main Business Overview

    • 11.2.5 GRAIL Latest Developments

  • 11.3 Burning Rock

    • 11.3.1 Burning Rock Company Information

    • 11.3.2 Burning Rock Multi Cancer Screening Product Offered

    • 11.3.3 Burning Rock Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Burning Rock Main Business Overview

    • 11.3.5 Burning Rock Latest Developments

  • 11.4 Thermo Fisher Scientific

    • 11.4.1 Thermo Fisher Scientific Company Information

    • 11.4.2 Thermo Fisher Scientific Multi Cancer Screening Product Offered

    • 11.4.3 Thermo Fisher Scientific Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Thermo Fisher Scientific Main Business Overview

    • 11.4.5 Thermo Fisher Scientific Latest Developments

  • 11.5 Exact Sciences Corporation

    • 11.5.1 Exact Sciences Corporation Company Information

    • 11.5.2 Exact Sciences Corporation Multi Cancer Screening Product Offered

    • 11.5.3 Exact Sciences Corporation Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Exact Sciences Corporation Main Business Overview

    • 11.5.5 Exact Sciences Corporation Latest Developments

  • 11.6 Fulgent Genetics

    • 11.6.1 Fulgent Genetics Company Information

    • 11.6.2 Fulgent Genetics Multi Cancer Screening Product Offered

    • 11.6.3 Fulgent Genetics Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Fulgent Genetics Main Business Overview

    • 11.6.5 Fulgent Genetics Latest Developments

  • 11.7 Genecast Biotechnology

    • 11.7.1 Genecast Biotechnology Company Information

    • 11.7.2 Genecast Biotechnology Multi Cancer Screening Product Offered

    • 11.7.3 Genecast Biotechnology Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Genecast Biotechnology Main Business Overview

    • 11.7.5 Genecast Biotechnology Latest Developments

  • 11.8 Agilent Technologies

    • 11.8.1 Agilent Technologies Company Information

    • 11.8.2 Agilent Technologies Multi Cancer Screening Product Offered

    • 11.8.3 Agilent Technologies Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Agilent Technologies Main Business Overview

    • 11.8.5 Agilent Technologies Latest Developments

  • 11.9 Atara Biotherapeutics

    • 11.9.1 Atara Biotherapeutics Company Information

    • 11.9.2 Atara Biotherapeutics Multi Cancer Screening Product Offered

    • 11.9.3 Atara Biotherapeutics Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Atara Biotherapeutics Main Business Overview

    • 11.9.5 Atara Biotherapeutics Latest Developments

  • 11.10 Konica Minolta

    • 11.10.1 Konica Minolta Company Information

    • 11.10.2 Konica Minolta Multi Cancer Screening Product Offered

    • 11.10.3 Konica Minolta Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Konica Minolta Main Business Overview

    • 11.10.5 Konica Minolta Latest Developments

  • 11.11 Tempus

    • 11.11.1 Tempus Company Information

    • 11.11.2 Tempus Multi Cancer Screening Product Offered

    • 11.11.3 Tempus Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Tempus Main Business Overview

    • 11.11.5 Tempus Latest Developments

  • 11.12 Myriad Genetics

    • 11.12.1 Myriad Genetics Company Information

    • 11.12.2 Myriad Genetics Multi Cancer Screening Product Offered

    • 11.12.3 Myriad Genetics Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Myriad Genetics Main Business Overview

    • 11.12.5 Myriad Genetics Latest Developments

  • 11.13 Laboratory Corporation

    • 11.13.1 Laboratory Corporation Company Information

    • 11.13.2 Laboratory Corporation Multi Cancer Screening Product Offered

    • 11.13.3 Laboratory Corporation Multi Cancer Screening Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Laboratory Corporation Main Business Overview

    • 11.13.5 Laboratory Corporation Latest Developments

• 12 Research Findings and Conclusion